Arterioscler Thromb Vasc Biol
COVID-19 linked to heightened CV risk up to 3 years later
October 14, 2024
COVID-19 requiring hospitalization represents a CAD risk equivalent. The magnitude of risk for post–acute MI and stroke is particularly high among individuals with non-O blood types.
Using data from the U.K. Biobank, investigators identified COVID-19 cases (n = 10,005) who had positive PCR-based tests for SARS-CoV-2 infection (n = 8,062) or received hospital-based ICD-10 codes for COVID-19 (n = 1,943) between February and December 2020. Population controls (n = 217,730) and propensity score—matched controls (n = 38,860) were drawn from the U.K. Biobank during the same period.
Risk of MACE was elevated in COVID-19 cases at all levels of severity (hazard ratio [HR], 2.09; 95% CI, 1.94–2.25), with more pronounced risk among in patients who were hospitalized for COVID-19 (HR, 3.85; 95% CI, 3.51–4.24). Because incident MACE risk among cases without CV disease history was even higher than that observed in COVID-19–noninfected patients with CV disease, hospitalization for COVID-19 represented a CAD risk equivalent. Risk of thrombotic events was increased in subjects with non-O blood types (HR, 1.65; 95% CI, 1.29–2.09) to a greater degree than those with blood type O (HR, 0.96; 95% CI, 0.66–1.39).
Source:
Hilser JR, et al. (2024, October 9). Arterioscler Thromb Vasc Biol. COVID-19 Is a Coronary Artery Disease Risk Equivalent and Exhibits a Genetic Interaction With ABO Blood Type. https://pubmed.ncbi.nlm.nih.gov/39381876/
TRENDING THIS WEEK